ARCHIVES

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

ASBMT Installs New Officers

March 14, 2003

Report Criticizes NIH Grant Review

June 16, 1995

In Brief: NCAB Approves Concept Of Converting Baltimore Program To Cancer Center; New DCCP Labs Named

June 5, 1981

NCAB Study Core Guideline Revisions; Final Decision To Await New Division BSC

May 23, 1980

Trastuzumab Showed Improved Survival In Stage IV Breast Cancer with CNS Metastases

August 26, 2011

DePinho’s Wife Was Briefed on AVEO Data 11 Days Before He Touted Stock on CNBC

September 13, 2013